Life sciences and healthcare
From corporate strategy and financing to protecting your innovations, we have the reach and sector experience to work with start-up ventures to multinational corporations across their life cycle.
Our experienced team of life sciences lawyers spanning the UK, Europe, US and Asia, advise a variety of clients, from leading academic institutions, established pharmaceutical and medical device companies, start-ups and tech accelerators to renowned charities.We’ve helped companies, specifically at inception or the early stages, bring innovative drugs, therapies and devices to market. Our team includes lawyers with scientific backgrounds, regulatory and diverse industry experience, which gives us a unique perspective of the opportunities and issues faced by our clients in the life sciences sector.
As trusted advisors to our clients, we often work as general counsel thereby extending the capabilities of their teams, as well as providing intellectual property and regulatory strategy and other legal services, including effective business structuring and capital raising advice, managing intellectual property and commercial arrangements, employment and tax.
Our dedicated life sciences team has extensive experience advising entrepreneurs, investors, and technology companies, operating in a range of sectors, including biotech, med-tech, food tech and health-tech (including digital health).
From inception to exit, we are familiar with the life cycle of life sciences companies and the demands on scaling your business. From structuring and fundraising for early stage companies to M&A and IPO for later stage companies.
We provide advice on a range of strategic regulatory matters, including:
- preclinical, clinical trials and post approval pharmacovigilance across multiple jurisdictions
- Interaction with regulatory authorities in the US and Europe
- advertising and promotional activities
- product recall and liability
- industry codes of conduct and compliance
- regulatory compliance regarding advertising and promotional activities
- petitions regarding matters before regulatory authorities
We understand the importance of protecting, enforcing and monetising your IP, and help with:
- IP strategy
- protecting IP developed by your employees, consultants and other third party service providers
- IP portfolio management and brand strategies to maximise the value of your IP across jurisdictions
- dispute resolution of IP infringement
- practitioners with advanced degrees in molecular biology and medicinal chemistry
- execution in IP prosecution in worldwide portfolios
- protection of bio-tech pharmaceutical and medical device technologies
We understand how critical it is for your business to have a strong development pipeline and commercialise your intellectual property. We help you:
- put in place valuable R&D, option and pipeline agreements to develop IP
- negotiate in-licensing and out-licensing agreements for early or late-stage products
- effectively bring your products to market through various outsourcing agreements for product manufacture, supply and distribution
For organizations whose business is simply growing beyond their existing legal capacity or which do not yet have budget for full time in-house lawyer, we offer general counsel support, whether at project specific fees and/or on a fixed monthly budget to meet your needs.
Our renowned charities team advises some of the leading charities in healthcare and research. We advise charities on governance and structuring issues where research is funded through charitable grants, social and financial investments. The team also advises organisations receiving charitable funding or investment.
Our team has a successful record of transferring technology and launching spin-out companies from notable universities, research institutions and tech accelerators. Our experience includes advising on investment and shareholder rights, and drafting and negotiating licensing documents and technology transfer agreements, including technology access through pipeline agreements, options and rights of first refusal.
experience. Susana Stanfield was particularly helpful, responsive and competent.
Have managed multiple deals for us in tandem professionally and calmly.
scientific knowledge, which is helpful to underpin the legal and drafting advice given.
Advice is available in a range of areas which spans our needs across our business.
GDPR advice has been a particularly helpful addition to the day-to-day.
Very responsive and thorough. Highly commercial. Give great confidence the interest
of the company will be well represented and that any risk area will be flagged. Access
to legal counsel in all areas.
A Cambridge-based clinical stage biotech company that leads in the inhibition of p300/CBP to treat multiple specific cancer types. CellCentric raised $33m to broaden clinical trials of its first-in-class p300/CBP inhibitor, CCS1477. We advised CellCentric with respect to this equity funding round from Morningside Venture Investments Limited and BridgeEdge, the impact venture capital fund of the American Cancer Society
Our UK and Boston Life Sciences team acts as General Counsel for In3Bio, an international biotech company on all legal matters worldwide dealing with high value negotiations and contracts with third parties including pre-clinical trials and Phase III clinical trials.
NRG Therapeutics - We advised Parkinson's UK on its investment which formed part of the $18.3m (£16m) Series A funding round of NRG Therapeutics to help progress the development of mitochondrial therapeutics to treat neurodegenerative ailments such as Parkinson’s disease and amyotrophic lateral sclerosis (ALS). Led by Omega Funds, the financing round also saw participation from new investor Brandon Capital. NRG Therapeutics is Cambridge based and leverages breakthrough science in the mitochondrial biology field to create disease-altering therapies to slow down or stop the progression of diseases such as Parkinson’s and ALS. This transaction combines the expertise of Wither Tech for venture capital and charities to help guide the innovative virtual biotech arm of Parkinson's UK in making this investment. Wither tech team also advises Parkinson's UK on intellectual property matters such as IP protection and funding agreements.
Roslin Tech is an Edinburgh-based food and agritech company that spun out of the Roslin Institute and has developed pluripotent animal stem cells with the capacity to self-renew indefinitely and differentiate into end-tissues for meat. The Withers tech team has advised food and agritech company Roslin Technologies Limited, on their £11 million Series A funding round. The financing was led by Novo Holdings, joined by Kairos Capital Group, Future Planet Capital, Esco Lifesciences, Alchimia, Nutreco and private investors. The Withers tech team also advises RoslinTech on commercial matters such as complex licensing and collaboration agreements and IP protection
Developed a worldwide patent portfolio
Secured emergency FDA approval
A New York based global life sciences investor
Advised a New York based global life sciences investor on a £20,000,000 investment into an Imperial College London spin-out company, VaxEquity Ltd, which accelerated the production of a vaccine to combat the Covid-19 pandemic and is dedicated to developing saRNA vaccines for serious and life-threatening diseases.
We advised biologics company Elasmogen Ltd on securing a £8 million investment round. The funding round was led by BGF and Scottish National Investment Bank with additional support from existing investor Scottish Enterprise.The Withers tech team also advises Elasmogen on commercial matters such as complex licensing and collaboration agreements and IP protection.
Acted for Medovate Limited
Acted for Medovate Limited, in respect of the set up and venture capital funding of this company established to enable and promote the commercialisation of intellectual property and medical products from NHS Trust in East Anglia.
Acting as General Counsel for In3Bio
Acting as General Counsel for In3Bio, an international biotech company on all legal matters worldwide dealing with high value negotiations and contracts with third parties including pre-clinical trials and Phase III clinical trials.
Global Access Diagnostics
Advised on the formation of GADx by the acquisition of two companies, Mologic and Global Access Diagnostics, by a consortium of social impact investors called Global Access Health. As part of this transition, GADx became a social enterprise, dedicating its profits and mission to improving the health and wellbeing of underserved populations around the world. We also advise on licensing and facilities agreements, manufacturing agreement and customer contracts.
Acquisition of the minority shareholding in Australian pharmaceutical company
We acted for Lupin in relation to its acquisition of the minority shareholding in a pharmaceutical company in Australia.
Acquisition of the U.S. subsidiary of a U.K. pharmaceutical company
Advised an Italian company in its acquisition of the U.S. subsidiary of a U.K. company in the pharmaceutical industry.
Biotech/healthcare merger and acquisition
Advised in the acquisition of and merger into a biotech/healthcare company based in North Carolina.
Reorganization of a leading Californian pharmaceutical company
Advised, as lead investor counsel, in a reorganization, US$1 million bridge loan, and US$7 million strategic investment by a leading pharmaceutical company in a biotech/medical company based in California.
Sale of the South Beach Diet brand to MidOcean Partners
We represented the founders of the South Beach Diet in the sale of the South Beach Diet brand to MidOcean Partners, a leading private equity firm.
Licensing of a new pharmaceutical drug product
Acted for an international pharmaceutical company in an evaluation project for the licensing of a new drug product as well as intellectual property litigation matters.
CEO of an international pharmaceutical company
We acted for the CEO of an international and award winning pharmaceutical company in relation to her acrimonious exit. As a co-founder of the business and a minority shareholder, we negotiated the terms of her multi-million pound settlement, working closing with one of the top four accountants on valuation issues.
US medical company
We were instructed to form a master LLC (limited liability company) to buy, build, own and occupy a state-of-the-art medical office building in the US. We also negotiated the permanent financing and construction, and arranged all the leases for our client.
The Global Rethinkers
People. Purpose. Progress
The most powerful forces for change come from rethinking. Without challenging the status quo we can't hope for change in business, in our communities or society at large.
We're getting behind some of the founders and innovators who are changing our world.
Check out our hub to find out more.
23 November 2023 | Article
The UK government's 'Independent review of university spin-out companies': transforming the UK into a tech and science superpower
Join the club
We have lots more news and information that you'll find informative and useful. Let us know what you're interested in and we'll keep you up to date on the issues that matter to you.
Our Boston team focuses on life sciences work, including regulatory and intellectual property issues. The team also represents clients investing in the life sciences industry, as well as clients commercializing life sciences and pharmaceutical innovations.
+1 617 613 9700
get in touchView office
Our Singapore team has strong expertise in the life sciences and healthcare sector. We advise on regulatory, commercialisation, finance, tax and intellectual property issues. We represent clients investing in the life sciences and healthcare industries, particularly investment funds, family offices and private companies.
+65 6535 6844
Get in touchview office
Get in touch
Our website will give you a flavour of the advice we provide - if you would like to talk to us for more information, please contact our client services team who will be happy to assist.